• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by TenX Keane Acquisition

    2/8/24 4:07:41 PM ET
    $TENK
    Blank Checks
    Finance
    Get the next $TENK alert in real time by email
    SC 13G 1 ef20020097_sc13g.htm SC 13G
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. ___)*

    TenX Keane Acquisition
    (Name of Issuer)
     
    Ordinary Shares, par value $0.0001 per share
    (Title of Class of Securities)
     
    G8708L104
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     
    ☒
    Rule 13d-1(b)

      ☐
    Rule 13d-1(c)

      ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    SCHEDULE 13G

    CUSIP No.
    G8708L104

    1
    NAMES OF REPORTING PERSONS
     
     
    Wolverine Asset Management, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Illinois
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     

     
     
     
     
    6
    SHARED VOTING POWER
     
     
    566,713
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    566,713
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    566,713
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.34%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IA
     
     
     
     

    Page 2 of 10

    CUSIP No.
    G8708L104


    1
    NAMES OF REPORTING PERSONS
     
     
    Wolverine Holdings, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Illinois
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     

     
     
     
     
    6
    SHARED VOTING POWER
     
     
    567,211
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    567,211
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    567,211
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.34%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC
     
     
     
     

    Page 3 of 10

    CUSIP No.
    G8708L104


    1
    NAMES OF REPORTING PERSONS
     
     
    Wolverine Trading Partners, Inc
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Illinois
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     

     
     
     
     
    6
    SHARED VOTING POWER
     
     
    567,211
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    567,211
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    567,211
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.34%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO/HC
     
     
     
     

    Page 4 of 10

    CUSIP No.
    G8708L104


    1
    NAMES OF REPORTING PERSONS
     
     
    Christopher L. Gust
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    US Citizen
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     

     
     
     
     
    6
    SHARED VOTING POWER
     
     
    567,211
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    567,211
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    567,211
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.34%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN/HC
     
     
     
     

    Page 5 of 10

    CUSIP No.
    G8708L104


    1
    NAMES OF REPORTING PERSONS
     
     
    Robert R. Bellick
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    US Citizen
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     

     
     
     
     
    6
    SHARED VOTING POWER
     
     
    567,211
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    567,211
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    567,211
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    6.34%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN/HC
     
     
     
     

    Page 6 of 10

    Item 1.
     
    (a)
    Name of Issuer:
     
    TenX Keane Acquisition
     
    (b)
    Address of Issuer’s Principal Executive Offices:
     
    420 Lexington Avenue, Suite 2446
    New York, NY 10170
     
    Item 2.
     
    (a)
    Name of Person Filing:
     
    Wolverine Asset Management, LLC
    Wolverine Holdings, L.P.
    Wolverine Trading Partners, Inc.
    Christopher L. Gust
    Robert R. Bellick
     
    (b)
    Address of Principal Business Office or, if None, Residence:
     
    c/o Wolverine Asset Management, LLC
    175 West Jackson Boulevard, Suite 340
    Chicago, IL 60604
     
    (c)
    Citizenship:
     
    Wolverine Asset Management, LLC — Illinois
    Wolverine Holdings, L.P. — Illinois
    Wolverine Trading Partners, Inc. — Illinois
    Christopher L. Gust — US Citizen
    Robert R. Bellick — US Citizen
     
    (d)
    Title and Class of Securities:
     
    Ordinary Shares, par value $0.0001 per share.
     
    (e)
    CUSIP No.:
     
    G8708L104
     
    Item 3.
    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     

    (a) 
    ☐
    Broker or dealer registered under Section 15 of the Act;
     

    (b) 
    ☐ 
    Bank as defined in Section 3(a)(6) of the Act;
     

    (c) 
    ☐
    Insurance company as defined in Section 3(a)(19) of the Act;
     
    Page 7 of 10


    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
     

    (e)
    ☒
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     

    (f) 
    ☐
    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
     

    (g) 
    ☒
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
     

    (h) 
    ☐
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     

    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
     

    (j)
    ☐
    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
     

    (k)
    ☐
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____
     
    Item 4.
    Ownership
     
    (a) Amount Beneficially Owned:
     
    Wolverine Asset Management, LLC (“WAM”) is an investment manager and has voting and dispositive power over 566,713 ordinary shares of the Issuer. The sole member and manager of WAM is Wolverine Holdings, L.P. (“Wolverine Holdings”). Robert R. Bellick and Christopher L. Gust may be deemed to control Wolverine Trading Partners, Inc. (“WTP”), the general partner of Wolverine Holdings. Each of Wolverine Holdings, Mr. Bellick, Mr. Gust, and WTP have voting and disposition power over 567,211 ordinary shares of the Issuer.
     
     (b)
    Percent of Class:  6.34%
     
    WAM may be deemed the beneficial owner of 6.34% of the Issuer’s outstanding ordinary shares and each of Wolverine Holdings, WTP, Mr. Bellick, and Mr. Gust may be deemed the beneficial owner of 6.34% of the Issuer’s outstanding ordinary shares. Percentages were calculated by dividing the number of shares deemed beneficially owned by each reporting person by 8,941,000 (the number of ordinary shares of the Issuer outstanding as of November 14, 2023 computed using the amount disclosed in the Issuer’s Form 10-Q for the quarter ended September 30, 2023 filed on November 20, 2023).
     
     (c)
    Number of shares as to which such person has:
     
     
    (i)
    Sole power to vote or to direct the vote:
     

    (ii)
    Shared power to vote or to direct the vote:
     
    WAM has shared power to vote or direct the vote of 566,713 ordinary shares of the Issuer, and each of Wolverine Holdings, WTP, Mr. Bellick, and Mr. Gust has shared power to vote or direct the vote of 567,211 ordinary shares of the Issuer, in each case as set forth in Item 4(a) above.
     
    (iii)
    Sole power to dispose or to direct the disposition of:
     

    (iv)
    Shared power to dispose or to direct the disposition of:
     
    WAM has shared power to dispose or direct the disposition of 566,713 ordinary shares of the Issuer, and each of Wolverine Holdings, WTP, Mr. Bellick, and Mr. Gust has shared power to dispose or direct the disposition of 567,211 ordinary shares of the Issuer, in each case as set forth in Item 4(a) above.
     

    Page 8 of 10

    Item 5.
    Ownership of Five Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
     
    Item 6.
    Ownership of more than Five Percent on Behalf of Another Person.
     
    Wolverine Flagship Fund Trading Limited is known to have the right to receive the receipt of dividends from, or the proceeds from the sale of, the ordinary shares of the Issuer covered by this statement that may be deemed to be beneficially owned by WAM.
     
    Item 7.
    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.
     
    Item 8.
    Identification and classification of members of the group.
     
    Item 9.
    Notice of Dissolution of Group.
     
    Item 10.
    Certifications.

    Page 9 of 10

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Dated:  February 1, 2024


    Wolverine Asset Management, LLC



    /s/ Kenneth L. Nadel

    Signature



    Kenneth L. Nadel, Chief Operating Officer

    Name/Title



    Wolverine Holdings, L.P.



    /s/Christopher L. Gust

    Signature



    Christopher L. Gust, Managing Director

    Name/Title



    Wolverine Trading Partners, Inc.



    /s/Christopher L. Gust

    Signature



    Christopher L. Gust, Authorized Signatory

    Name/Title



    /s/Christopher L. Gust

    Christopher L. Gust



    /s/ Robert R. Bellick

    Robert R. Bellick
     
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
     
    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).


    Page 10 of 10

    Get the next $TENK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TENK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TENK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

      TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) ("TenX"), a publicly traded special purpose acquisition company, was notified by The Nasdaq Stock Market that trading in TenX's securities had been halted for "additional information requested" from the company. The trading halt was imposed following volatility in the trading price and volume of TenX's securities on Wednesday, August 7, 202

      8/9/24 7:30:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance
    • TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

      TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "TenX"), a publicly traded special purpose acquisition company, today announced that on August 2, 2024, at the extraordinary general meeting, its shareholders voted to approve the previously announced business combination with the wholly own

      8/5/24 8:00:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance
    • Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

      Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction    Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J., Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane

      8/5/24 8:00:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance

    $TENK
    SEC Filings

    See more
    • SEC Form 25-NSE filed by TenX Keane Acquisition

      25-NSE - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/13/24 4:33:39 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 10-Q filed by TenX Keane Acquisition

      10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      8/9/24 4:22:23 PM ET
      $TENK
      Blank Checks
      Finance
    • TenX Keane Acquisition filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - TenX Keane Acquisition (0001851484) (Filer)

      8/2/24 8:45:17 PM ET
      $TENK
      Blank Checks
      Finance

    $TENK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TENK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 4 filed by Director Dutia Suren G

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:29:05 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 4 filed by Director Holubiak Myron Z

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:28:37 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 4 filed by Chief Medical Officer Czuczman Myron

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:28:05 PM ET
      $TENK
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13D/A filed by TenX Keane Acquisition

      SC 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/15/24 12:53:48 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by TenX Keane Acquisition (Amendment)

      SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)

      3/7/24 4:06:26 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form SC 13G filed by TenX Keane Acquisition

      SC 13G - TenX Keane Acquisition (0001851484) (Subject)

      2/13/24 8:09:57 PM ET
      $TENK
      Blank Checks
      Finance